LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
LENZ Therapeutics (NASDAQ: LENZ) has reported its Q4 and full year 2024 financial results, highlighting significant progress toward the potential approval of LNZ100 for presbyopia treatment. The FDA has set a PDUFA target action date of August 8, 2025, with no Advisory Committee Meeting planned.
Key financial metrics include:
- Cash position of $209.1 million as of December 31, 2024
- Q4 2024 R&D expenses decreased to $5.9 million from $19.5 million in Q4 2023
- Q4 2024 SG&A expenses increased to $9.4 million from $5.5 million in Q4 2023
- Q4 2024 net loss of $12.7 million ($0.46 per share)
The company has completed its mid-cycle review with the FDA and initiated production for commercial launch. Phase 3 study results in China showed positive outcomes, with 74% of patients achieving three-lines or greater improvement at 3 hours. Commercial preparations are advancing with expanded infrastructure and key sales force leadership appointments.
Positive
- Strong cash position of $209.1 million expected to fund operations through commercial launch
- Significant reduction in R&D expenses (76% decrease in Q4 2024 vs Q4 2023)
- Positive Phase 3 results in China with 74% efficacy rate
- FDA mid-cycle review completed with no significant issues identified
- Commercial infrastructure expansion progressing with key sales leadership appointments
Negative
- Increased SG&A expenses (71% increase in Q4 2024 vs Q4 2023)
- Continued net losses ($12.7 million in Q4 2024)
- Pre-revenue company dependent on FDA approval for commercialization
News Market Reaction
On the day this news was published, LENZ gained 3.06%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025
Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth quarter of 2025
Cash, cash equivalents and marketable securities of
Company to host a conference call today at 4:30 p.m. EST
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent corporate highlights.
“This year has been an extremely successful year for LENZ, and we have continued to make progress in the fourth quarter and recent period as we move closer to the potential approval and launch of LNZ100 in the United States,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “I am very pleased with the advancements made by our regulatory team with the FDA, having recently completed our mid-cycle review, which led to our manufacturing operations team initiating production to support our potential commercial launch. Importantly, the recent period has been highlighted by the focus and execution of our medical affairs team, continuing to educate the ECP community on the benefits of a pupil-selective, ciliary-body sparing miotic for the treatment of presbyopia, in addition to impressive pre-commercial planning efforts as we near completion of our full commercial infrastructure and finalized our branding creative. We look forward to highlighting much of this recent progress and more at our upcoming Commercial Day on April 15th.”
Fourth Quarter 2024 and Recent Corporate Highlights
Announced New Drug Application (NDA) acceptance by the U.S. Food and Drug Administration (FDA) for LNZ100 as a treatment for presbyopia. In October 2024, the Company announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia, a condition that impacts an estimated 1.8 billion people globally and 128 million people in the United States. The Company previously announced the submission of its NDA in August 2024. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100, and noted it is not planning to hold an Advisory Committee Meeting to discuss this application. In January 2025, the mid-cycle review meeting and communications were completed, noting no significant review issues. In the mid-cycle review communications, the FDA reiterated it had no plans to request an Advisory Committee Meeting. The NDA submission for the treatment of presbyopia is supported by positive data from the pivotal Phase 3 CLARITY study. Aceclidine is a new chemical entity in the United States and is not approved for the treatment of presbyopia in any country.
Pre-launch U.S. commercial planning advanced in preparation for potential August 2025 approval. The Commercial team advanced its commercial readiness for LNZ100 for the treatment of presbyopia as the Company progressed towards the August 8, 2025 PDUFA target action date. Now approaching its first anniversary date of the EYEAMSELECTIVE unbranded campaign, the awareness of the Eye Care Professional (ECP) community on the importance of a pupil-selective and ciliary-body sparing miotic continued to grow, with over 2 million digital campaign impressions targeting over 30,000 ECPs. In the fourth quarter 2024 and recent period, the Company further expanded its commercial infrastructure and hired key sales force leadership including Regional Sales Directors and all District Managers, adding substantial commercial eye care and pharmaceutical sales experience.
CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia. In October 2024, CORXEL and the Company announced topline data from the Phase 3 safety and efficacy study in China. In the Phase 3 study, LNZ100 (
LENZ to host Commercial Day on April 15, 2025. The Company will host a Commercial Day to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia. The event will take place on Tuesday, April 15, 2025, from 2:00 p.m. – 4:00 p.m. EST. The event will include presentations by management to feature key updates as the Company approaches the potential approval and launch of LNZ100, including commercialization strategies, supply chain and product distribution readiness and perspectives from Key Opinion Leader and ECPs. A live audio webcast of the presentation will be available through the link here and on the Events section of the Investor Relations page of the LENZ Therapeutics website at www.LENZ-tx.com.
Financial Results for Three Months and Year Ended December 31, 2024
Cash Position: Cash, cash equivalents and marketable securities were
Research and Development (R&D) Expenses: R&D expenses decreased to
Selling, General and Administrative (SG&A) Expenses: SG&A expenses were
Net Loss: Net loss for the three months ended December 31, 2024, was
Conference Call Information
The Company will host a conference call and webcast today, Wednesday, March 19, 2025, at 4:30 p.m. EST. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 9147301. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the review and potential approval of our NDA by FDA for the potential regulatory approval; approval and commercialization of LNZ100 as a global therapy; our plans relating to commercialization, including engagement with key opinion leaders and eye care professionals and the development of commercial capabilities; the size of the market opportunity for LNZ100; the beneficial characteristics of LNZ100 and its expected impact on presbyopes; our plans to host a Commercial Day and the subject matter to be discussed at such event; and expectations regarding shareholder value creation. These statements are based on numerous assumptions concerning the development of LENZ’s product candidates and target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled “Risk Factors” in our Annual Report on Form 10-K to be filed for the year ended December 31, 2024 and our subsequent filings with the SEC. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
| LENZ Therapeutics, Inc. Selected Consolidated Balance Sheets Highlights (in thousands) | ||||||
| December 31, | ||||||
| 2024 | 2023 | |||||
| Cash and cash equivalents | $ | 20,158 | $ | 35,140 | ||
| Marketable securities | 188,872 | 30,654 | ||||
| Total assets | 215,304 | 70,376 | ||||
| Total liabilities | 11,220 | 19,698 | ||||
| Total stockholders’ equity (deficit) | 204,084 | (92,712 | ) | |||
| LENZ Therapeutics, Inc. Consolidated Statement of Operations and Comprehensive Loss (in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 5,868 | $ | 19,536 | $ | 29,801 | $ | 59,504 | |||||||
| Selling, general and administrative | 9,357 | 5,453 | 28,809 | 12,925 | |||||||||||
| Total operating expenses | 15,225 | 24,989 | 58,610 | 72,429 | |||||||||||
| Loss from operations | (15,225 | ) | (24,989 | ) | (58,610 | ) | (72,429 | ) | |||||||
| Other income: | |||||||||||||||
| Other income | 8 | 267 | 289 | 93 | |||||||||||
| Interest income | 2,566 | 851 | 8,553 | 2,189 | |||||||||||
| Total other income, net | 2,574 | 1,118 | 8,842 | 2,282 | |||||||||||
| Net loss before income taxes | $ | (12,651 | ) | $ | (23,871 | ) | $ | (49,768 | ) | $ | (70,147 | ) | |||
| Income tax expense (benefit) | 1 | (179 | ) | 1 | (179 | ) | |||||||||
| Net loss | (12,652 | ) | (23,692 | ) | (49,769 | ) | (69,968 | ) | |||||||
| Other comprehensive income (loss): | |||||||||||||||
| Unrealized (loss) gain on marketable securities | (327 | ) | 11 | 190 | 6 | ||||||||||
| Comprehensive loss | $ | (12,979 | ) | $ | (23,681 | ) | $ | (49,579 | ) | $ | (69,962 | ) | |||
| Net loss per share, basic and diluted | $ | (0.46 | ) | $ | (12.04 | ) | $ | (2.34 | ) | $ | (35.71 | ) | |||
| Weighted-average common shares outstanding, basic and diluted | 27,492,616 | 1,967,434 | 21,281,038 | 1,959,091 | |||||||||||
FAQ
When is the FDA PDUFA date for LENZ Therapeutics' LNZ100 presbyopia treatment?
What were the Phase 3 clinical trial results for LENZ's LNZ100 in China?
How much cash does LENZ Therapeutics have as of Q4 2024?
What was LENZ Therapeutics' net loss per share in Q4 2024?
When does LENZ expect to commercially launch LNZ100?
